Morningstar

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

- Cordex Biologics, an ExCellThera company, is actively seeking strategic partnerships to accelerate the commercialization of Zemcelpro® in Europe and other markets MONTREAL, August 27, 2025 ...
ascopubs.org

Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial.

Comprehensive profiling of cancer associated cells in the blood of breast cancer patients to predict pathological complete response. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting ...
Seeking Alpha

EC approves Amicus' Pombiliti therapy for late-onset Pompe disease

Amicus Therapeutics (NASDAQ:FOLD) has received approval from the European Commission for its Pombiliti enzyme replacement therapy. The Commission approved Pombiliti as a long-term enzyme replacement ...

Sanofi, Lilly among winners of EU drug recommendations this week

During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new ...